

August 8, 2024

Nobelpharma Co., Ltd.

“Zintus® Tablets 50 mg” for Hypozincemia Launch

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura) announced that it will launch its hypozincemia treatment “Zintus® Tablets 50 mg” (generic name: zinc histidine hydrate) (this “Product”) on Tuesday, August 20.

Zinc, as an essential trace element in the body, is required for the activity of many enzymes indispensable in vital function and fulfills diverse roles depending on various clinical states and conditions. Hypozincemia is the zinc-deficient condition as serum zinc concentration decreases. Insufficient zinc is known to induce many different symptoms such as impaired taste, dermatitis, hair loss, anemia, oral inflammation, gonadal dysfunction, increased susceptibility to infection, pressure ulcer, loss of appetite, and developmental disturbance (pediatric).

“NOBELZIN® Tablets 25 mg/50mg/granules 5%” have already been on market for hypozincemia treatment, and this Product was approved on March 26 based on the results of the comparative study with the NOBELZIN tablets.

Better drug adherence is expected with this Product because it enables to supplement lost zinc with once-a-day dosage.

For Zintus® Tablets 25 mg, the drug price listing has been postponed this time from the perspective of stable supply and a further announcement will be made as it becomes ready.

We hope the launch of this Product will be of some help by providing a new option for zinc supplementation therapy and are determined to continue

contribution to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800